专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20050096390A1 Compositions comprising fenofibrate and pravastatin 审中-公开
标题翻译：包含非诺贝特和普伐他汀的组合物
公开(公告)号：US20050096390A1
公开(公告)日：2005-05-05
申请号：US10988818
申请日：2004-11-15
申请人： Per Holm , Tomas Norling
发明人： Per Holm , Tomas Norling
IPC分类号： A61K9/16 , A61K9/20 , A61K31/216 , A61K31/22 , A61K31/40 , A61K45/06 , A61K31/225 , A61K31/19
CPC分类号： A61K45/06 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2077 , A61K31/216 , A61K31/22 , A61K31/40 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor pravastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCpravastatin) of between about 90 and about 6300. The solid compositions are manufactured without any need of addition of water or aqueous medium and comprise at least 80% of the active substances fenofibrate and pravastatin in dissolved form, or, optionally, atorvastatin in micronized form, in order to ensure suitable bioavailability.
摘要翻译：本发明涉及颗粒形式的药物组合物或固体剂型，其包含非诺贝特和HMG CoA还原酶抑制剂普伐他汀或其药物活性盐的组合，其在口服给药时提供相对AUC 0-24 约90和约6300之间的值（AUC 纤维酸/ AUC 普伐他汀）。固体组合物在不需要添加水或水性介质的情况下制造，并且包括至少80％的非诺贝特活性物质和溶解形式的普伐他汀，或任选地以微粉化形式的阿伐他汀，以确保合适的生物利用度。

52. 发明申请

US20050053652A1 Pharmaceutical composition containing citalopram 审中-公开
标题翻译：含西酞普兰的药物组合物
公开(公告)号：US20050053652A1
公开(公告)日：2005-03-10
申请号：US10966725
申请日：2004-10-15
申请人： Ken Liljegren , Per Holm , Ole Nielsen , Sven Wagner
发明人： Ken Liljegren , Per Holm , Ole Nielsen , Sven Wagner
IPC分类号： A61K9/20 , A61K9/48 , A61K9/64 , A61K31/343 , C07D307/87 , A61K31/495
CPC分类号： C07D307/87 , A61K9/2054 , A61K9/4866 , A61K31/343
摘要： A solid unit dosage form comprising citalopram, which is prepared by direct compression of a mixture of citalopram base or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, or by filling of said mixture in a hard gelatine capsule. Large crystals of a pharmaceutical acceptable salt of citalopram and method for the manufacture of said large crystals.
摘要翻译：包含西酞普兰的固体单位剂型，其通过直接压制西酞普兰碱或其药学上可接受的盐和药学上可接受的赋形剂的混合物或通过将所述混合物填充在硬明胶胶囊中来制备。西酞普兰药物可接受盐的大晶体和用于制造所述大晶体的方法。

53. 发明授权

US06849659B2 Pharmaceutical composition containing citalopram 有权
公开(公告)号：US06849659B2
公开(公告)日：2005-02-01
申请号：US09730380
申请日：2000-12-05
申请人： Ken Liljegren , Per Holm , Ole Nielsen , Sven Wagner
发明人： Ken Liljegren , Per Holm , Ole Nielsen , Sven Wagner
摘要： A solid unit dosage form comprising citalopram, which is prepared by direct compression of a mixture of citalopram base or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, or by filling of said mixture in a hard gelatine capsule. Large crystals of a pharmaceutical acceptable salt of citalopram and method for the manufacture of said large crystals.

54. 发明授权

US5476667A Method for drug formulation and a pharmaceutical composition 失效
标题翻译：药物制剂的方法和药物组合物
公开(公告)号：US5476667A
公开(公告)日：1995-12-19
申请号：US39175
申请日：1993-04-16
申请人： Arne Kristensen , Per Holm
发明人： Arne Kristensen , Per Holm
IPC分类号： A61K9/14 , A61K9/16 , A61K31/43 , A61K31/606 , A61K31/616 , A61K31/655 , A61K47/34
CPC分类号： A61K9/1641 , A61K9/1694
摘要： A melt granulating method for the production of pellets (spheres) which contain a therapeutically active substance of high-dosage type. The method is characterized by: (i) mechanically working a mixture which contains (a) the active substance in cohesive form and (b) a binder (melting point 40.degree. C.-100.degree. C.) while supplying sufficient energy for the binder to melt and to form spherical overwetted pellets; (ii) adding further cohesive substance, while maintaining the mechanical working; (iii) interrupting the mechanical working and supply of energy and cohesive substance when the desired mean particle size of dry pellets (spheres) has been achieved; and (iv) removing the smallest and largest particles and dividing the remaining pellets into dosage batches. A novel pharmaceutical composition containing a dosage of 300-500 mg of pellets is obtainable from this process.
摘要翻译： PCT No.PCT / SE91 / 00690 Sec。 371日期：1993年04月16日 102（e）日期1993年4月16日PCT 1991年10月15日PCT PCT。公开号WO92 / 06679 日期：1992年4月30日。一种用于生产含有高剂量治疗活性物质的丸粒（球）的熔体造粒方法。该方法的特征在于：（i）机械加工包含（a）活性物质以粘结形式和（b）粘合剂（熔点为40℃-100℃）的混合物，同时为粘合剂提供足够的能量熔化并形成球形过湿颗粒; （ii）在保持机械加工的同时加入更多的粘性物质; （iii）当达到所需的干颗粒（球体）平均颗粒尺寸时，中断机械加工和能量供应和粘性物质; 和（iv）除去最小和最大的颗粒，并将剩余的颗粒分成剂量批料。从该方法可获得含有300-500mg粒料剂量的新型药物组合物。

55. 发明授权

US09549918B2 Stabilized tacrolimus composition 有权
标题翻译：稳定的他克莫司组合物
公开(公告)号：US09549918B2
公开(公告)日：2017-01-24
申请号：US13029304
申请日：2011-02-17
申请人： Nikolaj Skak , Per Holm
发明人： Nikolaj Skak , Per Holm
IPC分类号： A61K31/436 , A61K9/14 , A61K9/20
CPC分类号： A61K9/2013 , A61K9/145 , A61K9/2077 , A61K31/436 , Y10S514/885
摘要： The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.
摘要翻译：本发明涉及一种稳定的药物组合物，其包含在载体中包含他克莫司的固体分散体，其还包含稳定剂，所述稳定剂能够在组合物中提供低于7的pH，如在水中分散后测量的，并且防止或减少储存他克莫司的主要降解产物，特别是8-表维酮霉素。

56. 发明授权

US08535799B2 Controlled agglomeration 有权
标题翻译：受控聚集
公开(公告)号：US08535799B2
公开(公告)日：2013-09-17
申请号：US11711965
申请日：2007-02-27
申请人： Anders Burr , Michiel Ringkjøbing-Elema , Jannie Egeskov Holm , Per Holm , Birgitte Møllgaard , Kirsten Schultz
发明人： Anders Burr , Michiel Ringkjøbing-Elema , Jannie Egeskov Holm , Per Holm , Birgitte Møllgaard , Kirsten Schultz
IPC分类号： A61K47/02 , A61K9/10 , B01J2/00
CPC分类号： A61K9/1682 , A61K9/1611 , A61K9/1623 , A61K9/1641 , A61K9/1652 , A61K9/1694 , A61K9/2009 , A61K9/2018 , A61K9/2031 , B01J2/006 , B01J2/02 , Y10T428/24868 , Y10T428/24901 , Y10T428/29 , Y10T428/2982 , Y10T428/2991 , Y10T428/2998
摘要： A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5° C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material.
摘要翻译：通过受控的团聚法制备颗粒材料的方法，即能够控制粒度增长的方法。该方法特别适用于制备含有水溶性相对较低和/或经受化学分解的治疗和/或预防活性物质的药物组合物。该方法包括：将包含载体的第一组合物喷雾在第二组合物上，第二组合物的熔点为约5℃或更高，其存在于液体形式的第一组合物中，第二组合物包含固体形式的材料，第二组合物组合物具有最高温度对应于载体和/或载体组合物的熔点的温度，以及ii）混合或其它手段对其上喷涂第一组合物的第二组合物进行机械加工以获得颗粒材料。

57. 发明授权

US08486993B2 Solid dispersions comprising tacrolimus 有权
公开(公告)号：US08486993B2
公开(公告)日：2013-07-16
申请号：US13178280
申请日：2011-07-07
申请人： Per Holm
发明人： Per Holm
IPC分类号： A61K31/435 , A61K9/20
CPC分类号： A61K31/436 , A61K9/0053 , A61K9/10 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1641 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/2846 , A61K9/2893 , A61K31/00 , A61K31/439 , A61K31/4745 , Y10S514/885
摘要： A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.

58. 发明申请

US20120195965A1 SOLID DOSAGE FORM COMPRISING A FIBRATE 有权
标题翻译：固体剂型包含纤维素
公开(公告)号：US20120195965A1
公开(公告)日：2012-08-02
申请号：US13315030
申请日：2011-12-08
申请人： Per HOLM , Tomas NORLING
发明人： Per HOLM , Tomas NORLING
IPC分类号： A61K31/216 , B29B9/00 , A61P7/00 , A61K9/14 , A61K9/20
CPC分类号： A61K9/20 , A61K9/2013 , A61K9/2018 , A61K31/192 , A61K31/195 , A61K31/216 , A61K31/22 , A61K31/40 , A61K45/06 , A61K2300/00
摘要： The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.
摘要翻译：本发明提供稳定的固体剂型和药物组合物，其包含溶解在非水载体中的贝特类，例如非诺贝特，以确保相对于已知的贝特类制剂，口服给药后活性成分的生物利用度得到改善。

59. 发明授权

US08124125B2 Solid dosage form comprising a fibrate 有权
标题翻译：包含贝特类的固体剂型
公开(公告)号：US08124125B2
公开(公告)日：2012-02-28
申请号：US12642563
申请日：2009-12-18
申请人： Per Holm , Tomas Norling
发明人： Per Holm , Tomas Norling
IPC分类号： A61K9/20
CPC分类号： A61K9/20 , A61K9/2013 , A61K9/2018 , A61K31/192 , A61K31/195 , A61K31/216 , A61K31/22 , A61K31/40 , A61K45/06 , A61K2300/00
摘要： The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.
摘要翻译：本发明提供稳定的固体剂型和药物组合物，其包含溶解在非水载体中的贝特类，例如非诺贝特，以确保相对于已知的贝特类制剂，口服给药后活性成分的生物利用度得到改善。

60. 发明申请

US20120029009A1 Tacrolimus For Improved Treatment Of Transplant Patients 有权
标题翻译：他克莫司用于改善移植患者的治疗
公开(公告)号：US20120029009A1
公开(公告)日：2012-02-02
申请号：US13167420
申请日：2011-06-23
申请人： Robert D. Gordon , Per Holm , Anne-Marie Lademann , Tomas Norling
发明人： Robert D. Gordon , Per Holm , Anne-Marie Lademann , Tomas Norling
IPC分类号： A61K31/436 , A61P37/06
CPC分类号： A61K31/436 , A61K9/0053 , A61K9/1617 , A61K9/1641 , A61K9/1652 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/284 , A61K9/2846 , A61K9/4891 , A61K47/10 , Y10S514/885
摘要： An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
摘要翻译：包括作为活性物质他克莫司或其药学活性类似物的延长释放口服剂型，每天一次免疫抑制治疗有需要的患者，优选肾或肝移植患者。剂型长时间释放活性物质。它还提供改善的药物动力学参数，由于延长的和恒定的体内释放，包括显着降低的峰浓度，尽管与常规立即释放剂型和最近的改进释放他克莫司相比，尽管生物利用度增加，最大浓度的显着延长时间和更高的最小浓度剂型

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式